Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
  • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the invention relates to the treatment and prevention of precancerous cell formation in the colon in those patients at risk for developing such precancerous cells. It also relates to preventing recurrence of such cell formation in those having been treated for cancer of the colon.
• epithelial cells line crypts along the mucosal wall. Those epithelial cells which line the colon exposed surface and approximately the upper 2/3 of the crypt are normally non-proliferating, while those lining the lower 1/3 of the crypts are proliferating. As the proliferating cells migrate toward the upper portion of the crypt they transform and lose their proliferative ability. Ultimately the oldest cells are shed from the colon surface in the normal functioning of the colon. However, when the proliferating epithelial cells are induced to retain their proliferative capacity after reaching the upper 1/3 of the crypt, the normal process may go awry and microadenomas form. The proliferating cell, now at the surface of the colon continues to proliferate and a polyp develops.
• Polyps may be either benign or cancerous. Some never become cancerous, but it is believed that adenomatous polyps are the main precursors of colon cancer and that about 90% of colon cancers develop from adenomatous polyps. Most adenomas do not continue to grow in size, but those that do are more likely to develop malignant changes. Therefore, reducing the number of adenomas and/or preventing their growth substantially reduces the number of potential colon cancers in the future. Since subjects once treated for colon cancer have a much greater risk for developing further adenomas and cancers, potential adenoma prevention is extremely valuable in this population. The same may be said for close blood relatives of those treated for colon cancer, who may be at increased risk for adenoma and colon cancer development.
• Bile acids have been implicated as important cancer promoting agents. In the normal sequence of events, bile acids are conjugated with taurine and glycine, making them more hydrophilic. It is these conjugated bile acids that are primarily involved in the digestion of fat. The bulk of these are reabsorbed in the final segment of the small bowel. However some of the conjugated bile acids are not absorbed and pass further down the GI tract.
• Bacterial modification of the conjugated bile acids occurs in the lower intestine or colon. Two primary pathways are involved, deconjugation and dehydroxylation. Free bile acids are produced from the conjugate and removal of the 7-alpha hydroxyl group results in formation of secondary bile acids. Each of these steps changes the bile acid to a more lipophilic compound and to one which is more cytotoxic and more cancer promoting than the unmodified compound.
• the normal healthy control is believed to have a proper balance of bile acids. If the lipophilic/hydrophilic balance of the bile acid pool is significantly upset in the lipophilic direction, the bile acids may become toxic or harmful to the colonic epithelial cells. It is believed that as the lipophilic nature of the bile acid pool increases, the mucosal epithelial cells are more likely to be damaged by the presence of the secondary bile acids, especially deoxycholate. The damaged cells then begin the repair process which includes inducing cell proliferation. Repeated and frequent damage repeatedly induces proliferation and repair. The process of apoptosis or programmed cell death may also be affected.
• Figure 1 contains the data from column 1 of Tables I and II.
• Figure 2 provides the data from column III of Tables I and II.
• Figure 3 provides data which demonstrates that the rats treated with 6-FUDCA had aberrant crypt foci with fewer aberrant crypts.
• the present invention relates to the use of an active agent selected from the group consisting of 6-fluoroursodeoxycholic acid (6-FUDCA), a pharmaceutically acceptable salt of 6- FUDCA, and a pharmaceutically acceptable conjugate of 6-FUDCA for the preparation of a pharmaceutical composition for use for the reduction of the incidence of or for the prevention of at least one of colonic adenomas or colonic microadenomas in a mammal at risk of developing such adenomas or microadenomas or for reducing fecal deoxycholic acid in a mammal.
• the present invention is drawn to the treatment or prevention of colorectal cancer.
• the method involves the administration of an effective adenoma or microadenoma preventing amount of 6-fluoroursodeoxycholic acid (6-FUDCA) or a pharmaceutically acceptable salt or pharmaceutically acceptable conjugate thereof to a mammal in need of such treatment.
• the method prevents the formation and/or growth of precursor lesions of cancer, protects colonic mucosal epithelial cells from the damaging effects of an overly lipophilic bile acid pool exposure, and lowers the risk of adenoma development in patients at risk for such development.
• Methods for the prevention and treatment of colorectal cancer are disclosed.
• the methods find general use in the prevention of the formation of secondary bile acids, the reduction of deoxycholic acid, and the protection against cytotoxic effects of other bioacids and carcinogens.
• the method involves the administration of an effective amount of 6-fluoroursodeoxycholic acid (6-FUDCA) or a pharmaceutically acceptable salt or a pharmaceutically acceptable conjugate thereof to a mammal in need of such treatment.
• 6-fluoroursodeoxycholic acid 6-FUDCA
• a pharmaceutically acceptable salt or a pharmaceutically acceptable conjugate thereof 6 ⁇ -fluoroursodeoxycholic acid.
• 6-FUDCA chemical name: 3 ⁇ , 7 ⁇ -dihydroxy-6 ⁇ -fluoro- 5B-cholanoic acid
• 6-FUDCA is extremely resistant to bacterial dehydroxylation.
• the compound has a higher resistance to 7- dehydroxylation by intestinal bacterial flora, and accordingly a prolonged half-life as well as an increase in stability .
• 6-FUDCA is a hydrophilic, fluorinated derivative of ursodeoxycholic acid (UDCA).
• UDCA has been implicated in the chemoprevention of azoxymethane-induced colonic carcinogenesis.
• the present method is drawn to the use of 6-FUDCA the fluorinated derivative of UDCA for the prevention and treatment of colorectal cancer.
• 6-FUDCA has superior therapeutic properties when compared to UDCA.
• the physicochemical properties of 6-FUDCA demonstrate its improved cytoprotection.
• the water solubility of 6-FUDCA is higher than that of UDCA.
• the critical micellar concentration is slightly lower.
• the critical micellar pH of 6-FUDCA was also lower than that of UDCA.
• the retention time on C-18 reverse phase HPLC was different for the two fluorinated diastereoisomers. That of the 6- ⁇ -epimer, which predominated, was slightly lower than UDCA, indicating increased hydrophilicity with respect to UDCA.
• the invention relates to the single isomers or diastereoisomers of 6-FUDCA and mixtures thereof.
• 6-FUDCA has greater absorption capacity and a reduced bacterial metabolism as compared to UDCA. Thus, 6-FUDCA is very important in treating or preventing colorectal cancer or any class of disease characterized by promotion or progression due to the effects of toxic bile acids.
• 6-FUDCA relates to the ability of hydrophilic bile acid to displace hydrophobic and potentially toxic endogenous bile acids from the bile acid pool, and displacement of these hydrophobic bile acids from cellular membranes.
• high levels of fecal hydrophobic bile acids (deoxycholic acid in particular) are associated clinically with risk of development of colorectal cancer.
• Treatment with 6-FUDCA effectively reduces fecal deoxycholic acid levels in parallel with reduced incidence of tumor development.
• 6-FUDCA shows improved solubility, reduced critical micellar pH, lack of bacterial metabolism, and enhances the enrichment of the bile acid pool. These properties, and the increased hydrophilicity of 6-FUDCA underlie the improved cytoprotection demonstrated by 6-FUDCA
• compositions of 6-FUDCA include the alkali metal (preferably sodium and potassium) and alkaline earth metal (preferably calcium and magnesium) salts; most preferably sodium or potassium salts.
• Pharmaceutically acceptable conjugates of 6-FUDCA include conjugates thereof with glycine or taurine. Preferably, free 6-FUDCA is used in the present invention.
• the invention is primarily directed towards humans, farm animals, and pets; most preferably humans.
• the at risk population of one or more of the mammals to be treated includes those (1) having been diagnosed with colon cancer, colonic adenomas, and/or colonic microadenomas; and/or (2) having a close blood relative who has been diagnosed with colon cancer, colonic adenomas, and/or colonic microadenomas.
• the compounds of the invention are administered in the form of pharmaceutical compositions prepared accordingly to known techniques and excipients, as described e.g. in "Remington's Pharmaceutical Sciences Handbook,"hack Pub. Co., N.Y. USA.
• an “effective amount” is an amount sufficient to reduce fecal deoxycholic acid levels and/or to reduce the incidence of colonic adenomas or colonic microadenomas in a mammal.
• the effective amount may vary from patient to patient depending on various factors including the patient's conditions, progression of disease, size or weight of the patient, etc.
• the effective amount of 6-FUDCA, its salts and its conjugates is calculated on the amount of 6- FUDCA and is from about 1 mg/kg/day orally to about 30 mg/kg/day orally. Based upon the demonstrated metabolic stability of 6-FUDCA, efficacy may be achieved at a lower dose, preferably about 3 mg/kg/day to about 15 mg/kg/day; more preferably, about 5 mg/kg/day to about 8 mg/kg/day.
• the preferred administration route is oral.
• the dosage may be in one or more divided doses.
• the daily dose is given in 1-4, preferably 2-3 divided doses.
• Typical doses for an adult human of about 60 kg is 300 mg of 6-FUDCA from one to four times, preferably 1-3 times, most preferably 2-3 times a day.
• suitable pharmaceutical compositions comprise capsules, tablets, sugar-coated pills, syrups, granulates, solutions, vials.
• suitable pharmaceutical compositions comprise capsules, tablets, sugar-coated pills, syrups, granulates, solutions, vials.
• the compounds of the invention can also be administered by local profusion, before or after surgical operations in form of dispensable solutions or powders.
• the active agent can be formulated with standard excipients and appropriate coating materials to obtain immediate release, controlled release or sustained release dosage forms.
• excipients include, but are not limited to: titanium dioxide, talc; starch; microcrystalline cellulose, microgranular cellulose, casein formaldehyde, colloidal silicon dioxide; lubricants such as magnesium stearate; colorants such as iron oxide; Eudragit coating materials, polyvinyl pyrrolidone, polyethyleneglycols, alumina, carboxymethylcellulose, and gelatin.
• Alternative specific formulations are disclosed in U.S. Patent Nos. 3,859,437 and 4,263,272. Still other formulations will be readily apparent to those of ordinary skill in the pharmaceutical formulation art.
• mice Male albino Fischer-344 rats, initially weighing approximately 90-130 g, were used in these experiments. All diets were obtained from Dyets, Inc. (Bethlehem, PA). On arrival, the animals were quarantined for 1 week and then divided into the following experimental groups:
• Group 4 - AIN-76 diet plus piroxicam 75 ppm (included for a known positive drug control).
• Example 2 The protocol for this Example was the same as that for Example I except that 12 rats were included in each AOM-treated group and 6 rats in each control group. Carcinogen was administered on Days 14 and 21. The rats were then continued on the diets containing the experimental drugs for an additional 10 weeks.
• UDCA ursodeoxycholic
• 6-FUDCA 6-fluoroursodeoxycholic
• the first two Tables contain the data and statistical analysis of the data.
• the data from column 1 of Tables I and II are shown in Figure 1.
• Figure 2 provides the data from column HI of Tables I and II.
• the rats treated with 6-FUDCA had aberrant crypt foci with fewer aberrant crypts. This is important because it is the aberrant crypt foci with high multiplicity of aberrant crypts which are more apt to develop into neoplastic lesions.
• 6-FUDCA Because of the metabolic stability of 6-FUDCA and its ability to accumulate in the bile to a greater extent then does UDCA, the minimum effective dose of 6-FUDCA is predicted to be lower than that of UDCA.
• Table III shows that 6-FUDCA is not metabolized by bacteria in the gut. Thus, potentially toxic bile acids, deoxycholic acid and lithocholic acid do not accumulate.
• Table m provides an analysis of fecal bile acid levels in the experiment. It shows that 6-FUDCA accumulates to a greater degree then does UDCA (86.5% in the 6-FUDCA group versus 65.5% in the UDCA group). In addition, less DC and hyoDC are seen in the feces of 6-FUDCA rats than in UDCA rats. Therefore, 6-FUDCA enriches rat bile with therapeutic bile acid to a greater extent then can UDCA. Furthermore, 6-FUDCA reduces the formation of bile acids which are potentially toxic to the colonic mucosa.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Steroid Compounds (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=21786767

Family Applications (1)

Country Status (10)

Cited By (5)

Families Citing this family (28)

Citations (2)

Family Cites Families (1)

• 1997
  • 1997-05-22 CA CA002253593A patent/CA2253593C/en not_active Expired - Fee Related
  • 1997-05-22 ES ES97925934T patent/ES2306459T3/es not_active Expired - Lifetime
  • 1997-05-22 PT PT97925934T patent/PT906106E/pt unknown
  • 1997-05-22 AU AU30915/97A patent/AU3091597A/en not_active Abandoned
  • 1997-05-22 DE DE69738667T patent/DE69738667D1/de not_active Expired - Lifetime
  • 1997-05-22 AT AT97925934T patent/ATE394107T1/de not_active IP Right Cessation
  • 1997-05-22 EP EP97925934A patent/EP0906106B1/en not_active Expired - Lifetime
  • 1997-05-22 WO PCT/EP1997/002632 patent/WO1997044043A1/en not_active Ceased
  • 1997-05-22 JP JP09541562A patent/JP2000510858A/ja active Pending
• 2000
  • 2000-10-06 US US09/684,585 patent/US6426340B1/en not_active Expired - Fee Related
• 2009
  • 2009-11-02 JP JP2009252071A patent/JP2010059175A/ja not_active Withdrawn

Patent Citations (2)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events